
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.
Techniques and applications using magnetic bead technology This eBook covers the techniques and applications using…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
NIH Clinical Center On December 7, 2017 we published an article on this blog entitled ”Improving Candidate Selection: Translating Molecules…
On January 12, 2018, Endpoints News sponsored a breakfast panel at the 2018 JP Morgan Healthcare Conference (JPM18) in San…
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.…
Indoximod (1-methyl-D-tryptophan) In Chapter 2 of our 2017 book-length report, Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes…
Sign in to your account